Elizabeth Garrett-Mayer to Adenocarcinoma
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Adenocarcinoma.
Connection Strength
1.025
-
SPECT analysis of cardiac perfusion changes after whole-breast/chest wall radiation therapy with or without active breathing coordinator: results of a randomized phase 3 trial. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):778-85.
Score: 0.361
-
Cervical esophageal cancer: a population-based study. Head Neck. 2015 Jun; 37(6):808-14.
Score: 0.092
-
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44.
Score: 0.090
-
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):135-43.
Score: 0.085
-
The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol. 2008 Sep; 33(3):579-84.
Score: 0.061
-
A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 2008 Mar; 135(3):627-34.
Score: 0.059
-
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 01; 25(25):3965-70.
Score: 0.057
-
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar 07; 99(5):376-85.
Score: 0.055
-
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar; 69(3):526-31.
Score: 0.055
-
Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res. 2006 Feb 01; 66(3):1730-9.
Score: 0.051
-
Molecular classification of lung cancer: a cross-platform comparison of gene expression data sets. Chest. 2004 May; 125(5 Suppl):103S.
Score: 0.046
-
A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res. 2004 May 01; 10(9):2922-7.
Score: 0.011